Invitae (NVTAQ) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document and Entity Information
Entity Registrant Name	Invitae Corp
Entity Central Index Key	1501134
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		31,819,289
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$68,264	$107,027
Prepaid expenses and other current assets	3,889	2,616
Marketable securities	116,069
Total current assets	188,222	109,643
Property and equipment, net	18,180	15,672
Restricted cash	150	150
Marketable securities, noncurrent	10,181
Other assets	1,482	3,313
Total assets	218,215	128,778
Current liabilities
Accounts payable	1,123	2,862
Accrued liabilities	7,102	3,237
Capital lease obligation, current portion	1,428	1,524
Total current liabilities	9,653	7,623
Capital lease obligation, net of current portion	1,780	2,011
Other long-term liabilities	412	401
Liabilities related to early exercise of stock options	11	14
Total liabilities	11,856	10,049
Commitments and contingencies (Note 5)
Convertible preferred stock, $0.0001 par value; 0 and 141,131,524 shares authorized, 0 and 141,131,524 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively		202,305
Stockholders' deficit:
Preferred stock, $0.0001 par value; 20,000,000 and 0 shares authorized, no shares issued and outstanding as of March 31, 2015 and December 31, 2014
Common stock, $0.0001 par value; 400,000,000 and 160,131,524 shares authorized, 31,803,345 and 944,581 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	3
Accumulated other comprehensive loss	-26
Additional paid-in capital	310,199	1,604
Accumulated deficit	-103,817	-85,180
Total Stockholders' equity (deficit)	206,359	-83,576
Total liabilities, preferred stock, and stockholders' equity (deficit)	$218,215	$128,778

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets
Convertible preferred stock, par value (in dollars per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	0	141,131,524
Convertible preferred stock, shares issued	0	141,131,524
Convertible preferred stock, shares outstanding	0	141,131,524
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized shares	20,000,000	0
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	400,000,000	160,131,524
Common stock, shares issued	31,803,345	944,581
Common stock, shares outstanding	31,803,345	944,581

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Operations
Revenue	$1,229	$118
Costs and operating expenses:
Cost of revenue	3,199	611
Research and development	8,455	4,965
Selling and marketing	4,740	1,666
General and administrative	3,440	1,895
Total costs and operating expenses	19,834	9,137
Loss from operations	-18,605	-9,019
Interest and other income (expense), net	-4	3
Interest expense	-28	-17
Net loss	($18,637)	($9,033)
Net loss per share basic and diluted	($1.09)	($12.06)
Shares used in computing net loss per share, basic and diluted	17,063,463	749,048

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Comprehensive Loss
Net loss	($18,637)	($9,033)
Other comprehensive loss
Unrealized loss on available-for-sale marketable securities, net of tax	-26
Comprehensive loss	($18,663)	($9,033)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($18,637)	($9,033)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,017	471
Stock-based compensation	538	132
Amortization of premium on marketable securities	65
Loss on disposal of assets	15
Changes in operating assets and liabilities
Prepaid expenses and other current assets	-1,273	-229
Other assets	380	-191
Accounts payable	-1,775	326
Accrued expenses and other liabilities	1,487	327
Net cash used in operating activities	-18,183	-8,197
Cash flows from investing activities
Purchase of marketable securities	-130,841
Proceeds from maturities of marketable securities	4,500
Purchases of property and equipment	-1,116	-867
Net cash used in investing activities	-127,457	-867
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering, net of issuance costs	107,147
Proceeds from exercise of stock options	57	19
Capital lease principal payment	-327	-185
Net cash provided by (used in) financing activities	106,877	-166
Net decrease in cash and cash equivalents	-38,763	-9,230
Cash and cash equivalents at beginning of period	107,027	43,070
Cash and cash equivalents at end of period	68,264	33,840
Supplemental cash flow information
Interest paid	27	16
Supplemental cash flow information of non-cash investing and financing activities:
Conversion of convertible preferred stock to common stock	202,305
Purchases of property and equipment in accounts payable and accrued liabilities	$2,424	$49

Organization_and_description_o

Organization and description of business	3 Months Ended
	Mar. 31, 2015
Organization and description of business
Organization and description of business
	1. Organization and description of business
	Invitae Corporation (the “Company”) was incorporated in the state of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The Company has two laboratories: one in San Francisco, California and a second in Santiago, Chile. The Company’s current product is an assay of 221 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company operates in one segment.
	Reverse stock split
	In January 2015, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse split of the Company’s issued and outstanding common stock at a 1-for-6 ratio, which was effected on February 9, 2015. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. The financial statements have also been retroactively adjusted to reflect a proportional adjustment to the conversion ratio for each series of preferred stock that will be effected in connection with the reverse stock split.
	Initial public offering
	In February 2015, the Company completed an initial public offering (“IPO”) of its common stock. In connection with its IPO, the Company sold 7,302,500 shares of common stock at $16.00 per share for aggregate net proceeds of $105.7 million after underwriting discounts and commissions and offering expenses payable by the Company. This includes the exercise in full by the underwriters of their option to purchase up to 952,500 additional shares of common stock at the same price to cover over-allotments. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 23,521,889 shares of common stock.
	Upon the effectiveness of the Amended and Restated Certificate of Incorporation of the Company on February 12, 2015, the number of shares of capital stock the Company is authorized to issue was increased to 420,000,000 shares, of which 400,000,000 shares are common stock and 20,000,000 shares are preferred stock. Both the common stock and preferred stock have a par value of $0.0001 per share. There are no shares of preferred stock outstanding at March 31, 2015.
	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. general accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The results for the three months ended March 31, 2015 are not necessarily indicative of the results expected for the full fiscal year or any other periods.

Summary_of_significant_account

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2015
Summary of significant accounting policies
Summary of significant accounting policies
	2. Summary of significant accounting policies
	Principles of consolidation
	The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.  The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company believes judgment is involved in determining revenue recognition; the recoverability of long-lived assets; the fair value of the Company’s common stock; stock-based compensation expense; and income tax uncertainties. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.
	Customer concentration
	Significant customers are those which represent 10% or more of the Company’s total revenue for each period presented in the condensed consolidated statements of operations. For each significant customer, revenue as a percentage of total revenue was follows:
		Three Months Ended
		March 31,
	Customers	2015		2014
	Customer A	14	%	20	%
	Customer B	*		12	%
	Customer C	—		11	%
	*Less than 10% of total revenue
	Cash equivalents
	The Company considers all highly liquid marketable securities with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S government agency securities.
	Marketable securities
	All marketable securities, have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities in debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities less than 365 days as of the balance sheet date. Long-term marketable securities have maturities greater than 365 days as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income (loss). Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.
	Restricted cash
	Restricted cash consists of money market funds that serves as collateral for a credit card agreement at one of the Company’s financial institutions.
	Internal-use software
	The Company capitalizes third-party costs incurred in the application development stage to design and implement the software used in its tests and Invitae Family History Tool mobile application. Costs incurred in the application development stage of the software and mobile application are capitalized and will be amortized over an estimated useful life of three years on a straight line basis.
	During the three months ended March 31, 2015 and 2014, the Company capitalized $750,000 and $150,000, respectively, of software development costs.
	Deferred offering costs
	Deferred offering costs, which primarily consist of direct incremental legal, accounting and printer fees relating to the IPO, were initially capitalized. The deferred offering costs were subsequently offset against IPO proceeds upon the closing of the offering in February 2015. As of December 31, 2014, the Company capitalized $1.9 million of deferred offering costs in other assets on the consolidated balance sheets.
	Fair value of financial instruments
	The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, and accounts payable. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, and accounts payable, approximate fair value due to their short maturities.
	See Note 4, “Fair value measurements” for further information on the fair value of the Company’s financial instruments.
	Revenue recognition
	Revenue is generated from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome. Revenue associated with subsequent re-requisition services was de minimis for all periods presented.
	Revenue is recognized when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. The criterion for whether the fee is fixed or determinable and whether collectability is reasonably assured are based on management’s judgments. When evaluating collectability, in situations where contracted reimbursement coverage does not exist, the Company considers whether the Company has sufficient history to reliably estimate a payor’s individual payment patterns. The Company reviews the number of tests paid against the number of tests billed and the payor’s outstanding balance for unpaid tests to determine whether payments are being made at a consistently high percentage of tests billed and at appropriate amounts given the amount billed. The Company has not been able to demonstrate a predictable pattern of collectability, and therefore recognizes revenue when payment is received.
	Cost of revenue
	Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to physicians and includes expenses for personnel costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities. Costs associated with performing the Company’s test are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test.
	Foreign currency transactions
	The Company uses the U.S. dollar as its functional currency for its subsidiary in Chile. Foreign currency assets and liabilities are remeasured into U.S. dollars using the end of period exchange rates except for nonmonetary assets and liabilities, which are remeasured using historical exchange rates. Expenses are remeasured using an average exchange rate for the respective period. No revenue has been recorded in Chile for the periods presented. Gains or losses from foreign currency transactions are included in interest income and other income (expense), net, in the condensed consolidated statements of operations. Foreign currency transaction gains and losses have not been significant to the condensed consolidated financial statements for all periods presented.
	Net loss per common share
	Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive. Common shares subject to repurchase are excluded from the weighted-average shares. At March 31, 2015 and 2014, 17,907 and 48,439 shares subject to repurchase, respectively, are excluded from basic net loss per share calculation.
	Recent accounting pronouncements
	On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In August 2014, the FASB issued ASU No. 2014-15 (Subtopic 205- 40), Presentation of Financial Statements—Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which provides guidance about management’s responsibility to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The adoption of this standard is not expected to have an impact on the Company’s consolidated financial statements.

Balance_sheet_components

Balance sheet components	3 Months Ended
	Mar. 31, 2015
Balance sheet components
Balance sheet components
	3. Balance sheet components
	Cash equivalents and marketable securities
	The following is a summary of cash equivalents and marketable securities (in thousands).
		March 31, 2015
		Amortized			Gross			Gross			Estimated
		Cost			Unrealized			Unrealized			Fair
					Gains			Losses			Value
	Money market funds	$	24,430		$	—		$	—		$	24,430
	U.S. treasury notes	2,033			—			—			2,033
	U.S. government agency securities	163,376			1			(27		)	163,350
		$	189,839		$	1		$	(27	)	$	189,813
	Reported as:
	Cash equivalents										$	63,413
	Restricted cash										150
	Marketable securities										116,069
	Marketable securities, non-current										10,181
	Total cash equivalents, restricted cash and marketable securities										$	189,813
		December 31, 2014
		Amortized			Gross			Gross			Estimated
		Cost			Unrealized			Unrealized			Fair
					Gains			Losses			Value
	Money market funds	$	15,167		$	—		$	—		$	15,167
		$	15,167		$	—		$	—		$	15,167
	Reported as:
	Cash equivalents										$	15,017
	Restricted cash										150
	Total cash equivalents and restricted cash										$	15,167
	At March 31, 2015, the remaining contractual maturities of available-for-sale securities were less than 1.5 years. For the three months ended March 31, 2015, there were no realized gains or losses on the available-for-sale securities. There were no available-for-sale marketable securities held by the Company at December 31, 2014.
	Property and equipment, net
	Property and equipment consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Leasehold improvements	$	2,123		$	1,914
	Laboratory equipment	8,196			6,528
	Equipment under capital lease	6,585			3,735
	Computer equipment	1,349			1,156
	Internal-use software	1,551			800
	Software	45			31
	Furniture and fixtures	158			158
	Automobiles	20			—
	Construction-in-progress	2,617			4,853
	Total property and equipment, gross	22,644			19,175
	Accumulated depreciation and amortization	(4,464		)	(3,503		)
	Total property and equipment, net	$	18,180		$	15,672
	Included in the construction-in-progress balance as of December 31, 2014 was $2.9 million of capital lease equipment that had not been placed in service. This capital lease equipment was placed in service as of March 31, 2015.
	Accrued liabilities
	Accrued liabilities consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Accrued compensation and related expenses	$	1,929		$	1,439
	Accrued costs of equipment	2,313			—
	Accrued professional services	909			1,030
	Accrued costs for construction-in-progress	75			32
	Other	1,876			736
	Total accrued liabilities	$	7,102		$	3,237

Fair_value_measurements

Fair value measurements	3 Months Ended
	Mar. 31, 2015
Fair value measurements
Fair value measurements
	4. Fair value measurements
	Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity.
	The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:
	Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets.
	Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable.
	Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions.
	The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015
		Level 1		Level 2		Level 3		Total
	Financial assets:
	Money market funds	$	24,430	$	—	$	—	$	24,430
	U.S. treasury notes	2,033		—		—		2,033
	U.S. government agency securities	—		163,350		—		163,350
	Total financial assets	$	26,463	$	163,350	$	—	$	189,813
		December 31, 2014
		Level 1		Level 2		Level 3		Total
	Financial assets:
	Money market funds	$	15,167	$	—	$	—	$	15,167
	Total financial assets	$	15,167	$	—	$	—	$	15,167
	The Company’s debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar movements in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to, benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data.
	There were no transfers between Level 1 and Level 2 during the periods presented.

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and contingencies.
Commitments and contingencies
	5. Commitments and contingencies
	New Leases
	In March 2015, the Company leased additional space in San Francisco and Oakland, California. The leases expire in April and June 2017, respectively, and aggregate future minimum lease payments for these facilities are approximately $2.4 million.
	Contingencies
	On November 25, 2013, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, Endorecherche, Inc. and Myriad Genetics, Inc. (collectively, the Myriad Plaintiffs) filed a complaint in the District of Utah (the Utah Action), alleging that certain of the Company’s genetic testing services infringe certain claims of various U.S. Patents (collectively, the Myriad Patents). On November 26, 2013, the Company filed a complaint for declaratory judgment in the Northern District of California (the California Action), asserting that the Myriad Patents are invalid and the Company does not infringe them, and the Myriad Plaintiffs counterclaimed alleging that the Company infringes the Myriad Patents. Although the Utah Action was dismissed, on February 19, 2014, the Judicial Panel on Multidistrict Litigation granted the Myriad Plaintiffs’ motion to consolidate for pre-trial proceedings all actions concerning the Myriad Patents (the MDL Proceedings), with the MDL Proceedings taking place in the District of Utah. On January 23, 2015, the Myriad Plaintiffs stipulated to the dismissal with prejudice of all of their claims and granted the Company a covenant not to sue for all of the patents they had asserted against the Company. On January 26, 2015, the court issued an order dismissing the California Action with prejudice, thereby ending the litigation.
	The Company may become party to various other claims and complaints arising in the ordinary course of business. Management does not believe that any ultimate liability resulting from any of these claims will have a material adverse effect on its results of operations, financial condition, or liquidity. However, management cannot give any assurance regarding the ultimate outcome of these claims, and their resolution could be material to operating results for any particular period, depending upon the level of income for the period.

Stock_incentive_plans

Stock incentive plans	3 Months Ended
	Mar. 31, 2015
Stock incentive plans
Stock incentive plans
	6. Stock incentive plans
	Stock incentive plans
	In 2010, the Company adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors, and consultants under terms and provisions established by the Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market of the common stock on the grant date, as determined by the Board of Directors. The terms of options granted under the 2010 Plan may not exceed ten years.
	In January 2015, the Company adopted the 2015 Stock Incentive Plan, or the 2015 Plan, which became effective upon the closing of the IPO. The 2015 Plan had 4,370,452 shares of common stock reserved for future issuance at the time of its effectiveness, which included 120,452 shares under the 2010 Plan which were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards.
	Options granted generally vest over a period of four years. Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the grant vests upon the first anniversary of the employee’s date of hire, with the remainder of the shares vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule.
	2015 employee stock purchase plan
	In January 2015, the Company adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. A total of 325,000 shares of common stock are reserved for issuance under the ESPP. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. The ESPP provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. The Company has not determined the date on which the initial purchase period will commence under the ESPP.
	Summary of option activity
	Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except share and per share amounts and years):
		Shares		Stock		Weighted-		Weighted-average	Aggregate
		available		options		average		remaining	intrinsic
		for grant		outstanding		exercise		contractual life	value
						price		(years)
	Balances at December 31, 2014	276,805		1,923,332		$	4.37	8.9	$	15,946
	Additional shares reserved	4,370,452		—		—
	Granted	(144,070	)	144,070		$	13.98
	Cancelled	41,613		(41,613	)	$	5.41
	Exercised	—		(28,379	)	$	1.99
	Balances at March 31, 2015	4,544,800		1,997,410		$	5.07	8.74	$	23,341
	Options exercisable at March 31, 2015			546,810		$	2.01	7.94	$	8,063
	Options vested and expected to vest at March 31, 2015			1,947,699		$	5.03	8.73	$	22,852
	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money.
	The weighted-average fair value of options to purchase common stock granted was $10.78 and $2.89 per share in the three months ended March 31, 2015 and 2014, respectively.
	The fair value of options to purchase common stock vested was $484,000 and $62,000 in the three months ended March 31, 2015 and 2014, respectively.
	The intrinsic value of options to purchase common stock exercised was $364,000 and $88,000 in the three months ended March 31, 2015 and 2014, respectively.
	Early exercise of stock options
	The 2010 Plan allows for the granting of options that may be exercised before the options have vested. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser’s employment or services, at the price paid by the purchaser, and are not deemed to be issued for accounting purposes until those related shares vest. The amounts received in exchange for these shares have been recorded as a liability on the accompanying balance sheets and will be reclassified into common stock and additional paid-in-capital as the shares vest. The Company’s right to repurchase these shares generally lapses 1/4 after a one-year cliff then at a monthly rate of 1/48 thereafter.
	At March 31, 2015 and December 31, 2014, there were 17,907 and 23,903 shares of common stock outstanding, respectively, subject to the Company’s right of repurchase at prices ranging from $0.30 to $1.26 per share. At March 31, 2015 and December 31, 2014, the Company recorded $11,000 and $14,000, respectively, as liabilities associated with shares issued with repurchase rights.
	Stock-based compensation
	The fair value of share-based payments for option granted to employees and directors was estimated on the date of grant using the Black-Scholes option- pricing valuation model based on the following assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	6.03		6.03
	Expected volatility	83.8	%	86.6	%
	Risk-free interest rate	1.28	%	1.75 - 1.91%
	Dividend yield	—		—
	Stock-based compensation related to stock options granted to non- employees is recognized as the stock options are earned. The fair value of the stock options granted is calculated at each reporting date using the Black- Scholes option pricing model with the following assumptions: expected life is equal to the remaining contractual term of the award as of the measurement date ranging from 8.00 years to 9.12 years as of March 31, 2015, and 9.00 years to 9.35 years as of March 31, 2014, respectively; risk free rate is based on the U.S. Treasury Constant Maturity rate with a term similar to the expected life of the option at the measurement date; expected dividend yield of 0%; and volatility of 83.8% as of March 31, 2015, and 86.63% as of March 31, 2014, respectively.
	The following table summarizes stock-based compensation expense related to stock options for the three months ended March 31, 2015 and 2014 included in the condensed consolidated statements of operations as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Cost of revenue	$	76		$	6
	Research and development	213			62
	Selling and marketing	124			19
	General and administrative	125			45
	Total stock-based compensation expense	$	538		$	132
	As of March 31, 2015, unrecognized compensation expense related to unvested options, net of estimated forfeitures, was $6.2 million, which the Company expects to recognize on a straight-line basis over a weighted- average period of 3.3 years.

Net_loss_per_common_share

Net loss per common share	3 Months Ended
	Mar. 31, 2015
Net loss per common share
Net loss per common share
	7. Net loss per common share
	The following table presents the calculation of basic and diluted net loss per share for the three months ended March 31, 2015 and 2014 (in thousands, except share and per share amounts):
		Three Months Ended
		March 31,
		2015			2014
	Net loss	$	(18,637	)	$	(9,033	)
	Shares used in computing net loss per share, basic and diluted	17,063,463			749,048
	Net loss per share, basic and diluted	$	(1.09	)	$	(12.06	)
	The following outstanding common stock equivalents have been excluded from diluted net loss per share for the three months ended March 31, 2015 and 2014 because their inclusion would be anti-dilutive:
		Three Months Ended
		March 31,
		2015		2014
	Shares of common stock subject to outstanding options	1,997,410		1,615,581
	Shares of common stock subject to conversion from convertible preferred stock	—		13,521,900
	Shares of common stock subject to unvested early exercise of outstanding options subject to repurchase	17,907		48,439
	Total common stock equivalents	2,015,317		15,185,920

Geographic_information

Geographic information	3 Months Ended
	Mar. 31, 2015
Geographic information
Geographic information
	8. Geographic information
	Revenue by country is determined based on the billing address of the customer. The following presents revenue by country for the three months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	United States	$	974	$	97
	Canada	125		13
	Rest of world	130		8
	Total revenue	$	1,229	$	118
	Long-lived assets, net, by location are summarized as follows (in thousands):
		March 31,		December 31,
		2015		2014
	United States	$	16,451	$	13,858
	Chile	1,729		1,814
	Total long-lived assets, net	$	18,180	$	15,672

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary of significant accounting policies
Principles of consolidation
	Principles of consolidation
	The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.  The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company believes judgment is involved in determining revenue recognition; the recoverability of long-lived assets; the fair value of the Company’s common stock; stock-based compensation expense; and income tax uncertainties. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.
Customer concentration
	Customer concentration
	Significant customers are those which represent 10% or more of the Company’s total revenue for each period presented in the condensed consolidated statements of operations. For each significant customer, revenue as a percentage of total revenue was follows:
		Three Months Ended
		March 31,
	Customers	2015		2014
	Customer A	14	%	20	%
	Customer B	*		12	%
	Customer C	—		11	%
	*Less than 10% of total revenue
Cash equivalents
	Cash equivalents
	The Company considers all highly liquid marketable securities with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S government agency securities.
Marketable securities
	Marketable securities
	All marketable securities, have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities in debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities less than 365 days as of the balance sheet date. Long-term marketable securities have maturities greater than 365 days as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income (loss). Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.
Restricted cash
	Restricted cash
	Restricted cash consists of money market funds that serves as collateral for a credit card agreement at one of the Company’s financial institutions.
Internal-use software
	Internal-use software
	The Company capitalizes third-party costs incurred in the application development stage to design and implement the software used in its tests and Invitae Family History Tool mobile application. Costs incurred in the application development stage of the software and mobile application are capitalized and will be amortized over an estimated useful life of three years on a straight line basis.
	During the three months ended March 31, 2015 and 2014, the Company capitalized $750,000 and $150,000, respectively, of software development costs.
Deferred offering costs
	Deferred offering costs
	Deferred offering costs, which primarily consist of direct incremental legal, accounting and printer fees relating to the IPO, were initially capitalized. The deferred offering costs were subsequently offset against IPO proceeds upon the closing of the offering in February 2015. As of December 31, 2014, the Company capitalized $1.9 million of deferred offering costs in other assets on the consolidated balance sheets.
Fair value of financial instruments
	Fair value of financial instruments
	The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, and accounts payable. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, and accounts payable, approximate fair value due to their short maturities.
	See Note 4, “Fair value measurements” for further information on the fair value of the Company’s financial instruments.
Revenue recognition
	Revenue recognition
	Revenue is generated from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome. Revenue associated with subsequent re-requisition services was de minimis for all periods presented.
	Revenue is recognized when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. The criterion for whether the fee is fixed or determinable and whether collectability is reasonably assured are based on management’s judgments. When evaluating collectability, in situations where contracted reimbursement coverage does not exist, the Company considers whether the Company has sufficient history to reliably estimate a payor’s individual payment patterns. The Company reviews the number of tests paid against the number of tests billed and the payor’s outstanding balance for unpaid tests to determine whether payments are being made at a consistently high percentage of tests billed and at appropriate amounts given the amount billed. The Company has not been able to demonstrate a predictable pattern of collectability, and therefore recognizes revenue when payment is received.
Cost of revenue	Cost of revenue
	Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to physicians and includes expenses for personnel costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities. Costs associated with performing the Company’s test are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test.
Foreign currency transactions
	Foreign currency transactions
	The Company uses the U.S. dollar as its functional currency for its subsidiary in Chile. Foreign currency assets and liabilities are remeasured into U.S. dollars using the end of period exchange rates except for nonmonetary assets and liabilities, which are remeasured using historical exchange rates. Expenses are remeasured using an average exchange rate for the respective period. No revenue has been recorded in Chile for the periods presented. Gains or losses from foreign currency transactions are included in interest income and other income (expense), net, in the condensed consolidated statements of operations. Foreign currency transaction gains and losses have not been significant to the condensed consolidated financial statements for all periods presented.
Net loss per common share
	Net loss per common share
	Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive. Common shares subject to repurchase are excluded from the weighted-average shares. At March 31, 2015 and 2014, 17,907 and 48,439 shares subject to repurchase, respectively, are excluded from basic net loss per share calculation.
Recent accounting pronouncements
	Recent accounting pronouncements
	On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In August 2014, the FASB issued ASU No. 2014-15 (Subtopic 205- 40), Presentation of Financial Statements—Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which provides guidance about management’s responsibility to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The adoption of this standard is not expected to have an impact on the Company’s consolidated financial statements.

Summary_of_significant_account2

Summary of significant accounting policies (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of significant accounting policies
Schedule significant customer, revenue as a percentage
		Three Months Ended
		March 31,
	Customers	2015		2014
	Customer A	14	%	20	%
	Customer B	*		12	%
	Customer C	—		11	%

Balance_sheet_components_Table

Balance sheet components (Tables)	3 Months Ended
	Mar. 31, 2015
Balance sheet components
Schedule cash, cash equivalents, short-term investments, and long-term investments
	The following is a summary of cash equivalents and marketable securities (in thousands).
		March 31, 2015
		Amortized			Gross			Gross			Estimated
		Cost			Unrealized			Unrealized			Fair
					Gains			Losses			Value
	Money market funds	$	24,430		$	—		$	—		$	24,430
	U.S. treasury notes	2,033			—			—			2,033
	U.S. government agency securities	163,376			1			(27		)	163,350
		$	189,839		$	1		$	(27	)	$	189,813
	Reported as:
	Cash equivalents										$	63,413
	Restricted cash										150
	Marketable securities										116,069
	Marketable securities, non-current										10,181
	Total cash equivalents, restricted cash and marketable securities										$	189,813
		December 31, 2014
		Amortized			Gross			Gross			Estimated
		Cost			Unrealized			Unrealized			Fair
					Gains			Losses			Value
	Money market funds	$	15,167		$	—		$	—		$	15,167
		$	15,167		$	—		$	—		$	15,167
	Reported as:
	Cash equivalents										$	15,017
	Restricted cash										150
	Total cash equivalents and restricted cash										$	15,167
Schedule of Property and equipment
	Property and equipment consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Leasehold improvements	$	2,123		$	1,914
	Laboratory equipment	8,196			6,528
	Equipment under capital lease	6,585			3,735
	Computer equipment	1,349			1,156
	Internal-use software	1,551			800
	Software	45			31
	Furniture and fixtures	158			158
	Automobiles	20			—
	Construction-in-progress	2,617			4,853
	Total property and equipment, gross	22,644			19,175
	Accumulated depreciation and amortization	(4,464		)	(3,503		)
	Total property and equipment, net	$	18,180		$	15,672
Schedule of Accrued liabilities
	Accrued liabilities consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Accrued compensation and related expenses	$	1,929		$	1,439
	Accrued costs of equipment	2,313			—
	Accrued professional services	909			1,030
	Accrued costs for construction-in-progress	75			32
	Other	1,876			736
	Total accrued liabilities	$	7,102		$	3,237

Fair_value_measurements_Tables

Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair value measurements
Financial instruments at fair value on a recurring basis
	The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015
		Level 1		Level 2		Level 3		Total
	Financial assets:
	Money market funds	$	24,430	$	—	$	—	$	24,430
	U.S. treasury notes	2,033		—		—		2,033
	U.S. government agency securities	—		163,350		—		163,350
	Total financial assets	$	26,463	$	163,350	$	—	$	189,813
		December 31, 2014
		Level 1		Level 2		Level 3		Total
	Financial assets:
	Money market funds	$	15,167	$	—	$	—	$	15,167
	Total financial assets	$	15,167	$	—	$	—	$	15,167

Stock_incentive_plans_Tables

Stock incentive plans (Tables)	3 Months Ended
	Mar. 31, 2015
Stock incentive plans
Schedule of activity under the 2015 plan
	Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except share and per share amounts and years):
		Shares		Stock		Weighted-		Weighted-average	Aggregate
		available		options		average		remaining	intrinsic
		for grant		outstanding		exercise		contractual life	value
						price		(years)
	Balances at December 31, 2014	276,805		1,923,332		$	4.37	8.9	$	15,946
	Additional shares reserved	4,370,452		—		—
	Granted	(144,070	)	144,070		$	13.98
	Cancelled	41,613		(41,613	)	$	5.41
	Exercised	—		(28,379	)	$	1.99
	Balances at March 31, 2015	4,544,800		1,997,410		$	5.07	8.74	$	23,341
	Options exercisable at March 31, 2015			546,810		$	2.01	7.94	$	8,063
	Options vested and expected to vest at March 31, 2015			1,947,699		$	5.03	8.73	$	22,852
Schedule of assumptions used in determination of fair value of options using Black Scholes model
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	6.03		6.03
	Expected volatility	83.8	%	86.6	%
	Risk-free interest rate	1.28	%	1.75 - 1.91%
	Dividend yield	—		—
Summary of stock based compensation expense related to stock options included in the condensed consolidated statements of operations
	The following table summarizes stock-based compensation expense related to stock options for the three months ended March 31, 2015 and 2014 included in the condensed consolidated statements of operations as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Cost of revenue	$	76		$	6
	Research and development	213			62
	Selling and marketing	124			19
	General and administrative	125			45
	Total stock-based compensation expense	$	538		$	132

Net_loss_per_common_share_Tabl

Net loss per common share (Tables)	3 Months Ended
	Mar. 31, 2015
Net loss per common share
Schedule of Earnings per share, basic and diluted
	The following table presents the calculation of basic and diluted net loss per share for the three months ended March 31, 2015 and 2014 (in thousands, except share and per share amounts):
		Three Months Ended
		March 31,
		2015			2014
	Net loss	$	(18,637	)	$	(9,033	)
	Shares used in computing net loss per share, basic and diluted	17,063,463			749,048
	Net loss per share, basic and diluted	$	(1.09	)	$	(12.06	)
Schedule of Antidilutive securities excluded from computation of earnings per share
		Three Months Ended
		March 31,
		2015		2014
	Shares of common stock subject to outstanding options	1,997,410		1,615,581
	Shares of common stock subject to conversion from convertible preferred stock	—		13,521,900
	Shares of common stock subject to unvested early exercise of outstanding options subject to repurchase	17,907		48,439
	Total common stock equivalents	2,015,317		15,185,920

Geographic_information_Tables

Geographic information (Tables)	3 Months Ended
	Mar. 31, 2015
Geographic information
Schedule of Revenue by country
	Revenue by country is determined based on the billing address of the customer. The following presents revenue by country for the three months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	United States	$	974	$	97
	Canada	125		13
	Rest of world	130		8
	Total revenue	$	1,229	$	118
Schedule of long-lived assets by location
	Long-lived assets, net, by location are summarized as follows (in thousands):
		March 31,		December 31,
		2015		2014
	United States	$	16,451	$	13,858
	Chile	1,729		1,814
	Total long-lived assets, net	$	18,180	$	15,672

Organization_and_description_o1

Organization and description of business (Details) (USD $)	0 Months Ended	3 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 12, 2015	Mar. 31, 2015	Jan. 31, 2015	Feb. 28, 2015	Dec. 31, 2014
		segment
		item
Number of laboratories		2
Number of operating segments		1
Number of common stock shares issued		31,803,345			944,581
Shares authorized	420,000,000
Common stock, shares authorized		400,000,000			160,131,524
Preferred stock, authorized shares		20,000,000			0
Common stock, par value (in dollars per share)		$0.00			$0.00
Preferred stock, par value (in dollars per share)		$0.00			$0.00
Preferred stock, shares outstanding		0			0
IPO
Common stock, par value (in dollars per share)	0.0001
Preferred stock, par value (in dollars per share)	0.0001
Common Stock
Reverse Stock Split, conversion ratio			0.1667
Common Stock | IPO
Number of common stock shares issued				7,302,500
Sale price on common stock (in dollars per share)				$16
Net proceeds from issue of common stock				$105.70
Number of common stock shares converted from preferred stock				23,521,889
Common stock, shares authorized	400,000,000
Preferred Stock | IPO
Preferred stock, authorized shares	20,000,000
Maximum | Common Stock | IPO
Number additional shares on common stock can be purchased by underwriters				952,500
California
Number of laboratories		1
CHILE
Number of laboratories		1

Summary_of_significant_account3

Summary of significant accounting policies (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Customer A
Concentration risk (as a percent)	14.00%	20.00%
Customer B
Concentration risk (as a percent)		12.00%
Customer C
Concentration risk (as a percent)		11.00%
Revenue | Customer Concentration Risk
Concentration risk (as a percent)	10.00%

Summary_of_significant_account4

Summary of significant accounting policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Software development costs incurred and capitalized	$750,000	$150,000
Deferred offering costs			$1,900,000
Shares subject to repurchase, excluded from basic loss per share calculation	2,015,317	15,185,920
Unvested early exercise of outstanding options subject to repurchase
Shares subject to repurchase, excluded from basic loss per share calculation	17,907	48,439

Balance_sheet_components_Detai

Balance sheet components (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Investment Holdings [Line Items]
Amortized Cost	$189,839	$15,167
Gross Unrealized Gains	1
Gross Unrealized Losses	-27
Estimated Fair Value	189,813	15,167
Reported as:
Cash equivalents	63,413	15,017
Restricted cash	150	150
Marketable securities	116,069
Marketable securities, noncurrent	10,181
Estimated Fair Value	189,813	15,167
Remaining contractual maturities	1 year 6 months
Marketable available-for-sale securities		0
Money market funds
Investment Holdings [Line Items]
Amortized Cost	24,430	15,167
Estimated Fair Value	24,430	15,167
Reported as:
Estimated Fair Value	24,430	15,167
U.S. treasury notes
Investment Holdings [Line Items]
Amortized Cost	2,033
Estimated Fair Value	2,033
Reported as:
Estimated Fair Value	2,033
US government agency securities
Investment Holdings [Line Items]
Amortized Cost	163,376
Gross Unrealized Gains	1
Gross Unrealized Losses	-27
Estimated Fair Value	163,350
Reported as:
Estimated Fair Value	163,350
Available-for-sale Securities.
Investment Holdings [Line Items]
Gross Unrealized Gains	0
Gross Unrealized Losses	$0

Balance_sheet_components_Detai1

Balance sheet components (Details 2) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property and equipment
Total property and equipment, gross	$22,644,000	$19,175,000
Accumulated depreciation and amortization	-4,464,000	-3,503,000
Total property and equipment, net	18,180,000	15,672,000
Leasehold improvements
Property and equipment
Total property and equipment, gross	2,123,000	1,914,000
Laboratory equipment
Property and equipment
Total property and equipment, gross	8,196,000	6,528,000
Equipment under capital lease
Property and equipment
Total property and equipment, gross	6,585,000	3,735,000
Computer equipment
Property and equipment
Total property and equipment, gross	1,349,000	1,156,000
Internal-use software
Property and equipment
Total property and equipment, gross	1,551,000	800,000
Software
Property and equipment
Total property and equipment, gross	45,000	31,000
Furniture and fixtures
Property and equipment
Total property and equipment, gross	158,000	158,000
Automobiles
Property and equipment
Total property and equipment, gross	20,000
Construction-in-progress
Property and equipment
Total property and equipment, gross	2,617,000	4,853,000
Capital lease equipment not placed in service		$2,900,000

Balance_sheet_components_Detai2

Balance sheet components (Details 3) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued liabilities
Accrued compensation and related expenses	$1,929	$1,439
Accrued costs of equipment	2,313
Accrued professional services	909	1,030
Accrued costs for construction-in-progress	75	32
Other	1,876	736
Total accrued liabilities	$7,102	$3,237

Fair_value_measurements_Detail

Fair value measurements (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Total financial assets	$189,813	$15,167
Transfers from Level 1 to Level 2	0	0
Transfers from Level 2 to Level 1	0	0
Recurring basis
Total financial assets	189,813	15,167
Recurring basis | Level 1
Total financial assets	26,463	15,167
Recurring basis | Level 2
Total financial assets	163,350
Money market funds | Recurring basis
Total financial assets	24,430	15,167
Money market funds | Recurring basis | Level 1
Total financial assets	24,430	15,167
U.S. treasury notes
Total financial assets	2,033
U.S. treasury notes | Recurring basis
Total financial assets	2,033
U.S. treasury notes | Recurring basis | Level 1
Total financial assets	2,033
US government agency securities
Total financial assets	163,350
Government sponsored entities | Recurring basis
Total financial assets	163,350
Government sponsored entities | Recurring basis | Level 2
Total financial assets	$163,350

Commitments_and_contingencies_

Commitments and contingencies (Details) (New Leases, USD $)	Mar. 31, 2015
In Millions, unless otherwise specified
New Leases
Future minimum lease payments under operating leases
Future minimum lease payments	$2.40

Stock_incentive_plans_Details

Stock incentive plans (Details) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2010	Mar. 31, 2014	Dec. 31, 2014	Jan. 31, 2015
Stock incentive plans
Stock incentive plan
Vesting rate upon the first anniversary (as a percent)	25.00%
Monthly vesting rate thereafter (as a percent)	2.08%
Activity under the plan
Additional shares reserved					4,370,452
Stock incentive plans | Minimum
Stock incentive plan
Employees holding voting rights of all classes of stock (as a percent)		10.00%
Exercise price of options on common stock (as a percent)		110.00%
Stock incentive plans | Maximum
Stock incentive plan
Term of options granted		10 years
Stock incentive plans | Options
Activity under the plan
Shares available for grant	4,544,800			276,805
Additional shares reserved	4,370,452
Balance at the beginning of the period	1,923,332				1,923,332
Granted (in shares)	144,070
Cancelled (in shares)	-41,613
Exercised (in shares)	-28,379
Balance at the end of the period	1,997,410			1,923,332
Weighted-average exercise price
Balance at the beginning of the period (in dollars per share)	4.37				4.37
Granted (in dollars per share)	13.98
Cancelled (in dollars per share)	5.41
Exercised (in dollars per share)	1.99
Balance at the end of the period (in dollars per share)	5.07			$4.37
Additional information
Weighted-average remaining contractual life	8 years 8 months 27 days			8 years 10 months 24 days
Aggregate intrinsic value	23,341			$15,946
Exercisable, Number of shares	546,810
Exercisable, weighted-average exercise price (in dollars per share)	2.01
Exercisable, weighted-average remaining contractual life	7 years 11 months 9 days
Exercisable, aggregate intrinsic value	8,063
Vested and expected to vest
Number of shares	1,947,699
Weighted-average exercise price (in dollars per share)	5.03
Weighted-average remaining contractual life	8 years 8 months 23 days
Aggregate intrinsic value	22,852
Weighted-average grant date fair value (in dollars per share)	10.78		$2.89
Fair value of options granted	484		62
Exercised, aggregate intrinsic value	364		$88
2010 Plan
Activity under the plan
Additional shares reserved					120,452
ESPP
Stock incentive plan
Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date (as a percent)					85.00%
Activity under the plan
Additional shares reserved					325,000

Stock_incentive_plans_Details_

Stock incentive plans (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Stock incentive plan
Liabilities associated with shares issued with repurchase rights	$11,000	$14,000
Options | 2010 Plan
Stock incentive plan
Repurchase of options before the end of year one (as a percent)	25.00%
Monthly repurchase of options after the end of year one (as a percent)	2.08%
Number of shares outstanding eligible for repurchase	17,907	23,903
Minimum price at which options may be repurchased (in dollars per share)	$0.30
Maximum price at which options may be repurchased (in dollars per share)	$1.26
Liabilities associated with shares issued with repurchase rights	$11,000	$14,000

Stock_incentive_plans_Details_1

Stock incentive plans (Details 3)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Options
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Expected term (in years)	6 years 11 days	6 years 11 days
Expected volatility	83.80%	86.60%
Risk-free interest rate	1.28%
Non-Employee Options
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Dividend yield	0.00%	0.00%
Expected volatility	83.80%	86.63%
Minimum
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Risk-free interest rate		1.75%
Minimum | Options
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Risk-free interest rate		1.91%
Minimum | Non-Employee Options
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Expected term (in years)	8 years	9 years
Maximum
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Risk-free interest rate		1.91%
Maximum | Non-Employee Options
Assumptions used in determination of fair value of options using the Black Scholes option pricing valuation model
Expected term (in years)	9 years 1 month 13 days	9 years 4 months 6 days

Stock_incentive_plans_Details_2

Stock incentive plans (Details 4) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock-based compensation
Total stock based compensation expense	$538,000	$132,000
Unrecognized stock based compensation	6,200,000
Expected period to recognize on a straight line basis	3 years 3 months 18 days
Cost of revenue.
Stock-based compensation
Total stock based compensation expense	76,000	6,000
Research and development
Stock-based compensation
Total stock based compensation expense	213,000	62,000
Selling and marketing
Stock-based compensation
Total stock based compensation expense	124,000	19,000
General and administrative
Stock-based compensation
Total stock based compensation expense	$125,000	$45,000

Net_loss_per_common_share_Deta

Net loss per common share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net loss per share
Net loss	($18,637)	($9,033)
Shares used in computing net loss per share, basic and diluted	17,063,463	749,048
Net loss per share, basic and diluted	($1.09)	($12.06)
Antidilutive shares excluded from diluted net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,015,317	15,185,920
Options
Antidilutive shares excluded from diluted net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,997,410	1,615,581
Conversion from preferred stock
Antidilutive shares excluded from diluted net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		13,521,900
Unvested early exercise of outstanding options subject to repurchase
Antidilutive shares excluded from diluted net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,907	48,439

Geographic_information_Details

Geographic information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Geographic information
Revenue	$1,229	$118
Total Long-lived assets, net	18,180		15,672
UNITED STATES
Geographic information
Revenue	974	97
Total Long-lived assets, net	16,451		13,858
Canada
Geographic information
Revenue	125	13
Rest of World
Geographic information
Revenue	130	8
CHILE
Geographic information
Total Long-lived assets, net	$1,729		$1,814